ClinTec International and Elephant Capital Complete Strategic £8 Million Investment Deal
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
ClinTec International, a global Clinical Research Organization (CRO) announces a financial and strategic partnership with Elephant Capital Plc., an AIM market listed private equity firm.
With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, Jim Hauslein, have also made personal co-investments in this transaction.
ClinTec has elected to strengthen the Board of the company as part of the transaction, and as such Gaurav Burman, Dr Anand Burman and Jim Hauslein will take up seats on the Board. Gaurav Burman founded Elephant Capital in 2007; the company counts some of the leading financial institutional investors in the UK and Europe amongst its shareholders and is actively supported by the Burman family itself.
Dr Anand Burman is the Chairman of FMCG company Dabur, and brings a wealth of experience in the healthcare sector and oncology. Jim Hauslein, who has previously served as Chairman and CEO of Sunglass Hut International, which was turned into a global enterprise during his tenure, provides invaluable business experience of growing corporates internationally.
Elephant focuses on differentiated businesses which are able to leverage the potential India holds as an emerging powerhouse within the global economy. ClinTec was identified as just such a company, as it has established a solid presence in India and is one of the first-movers in the Clinical Research Services arena to enter India in 2002.
Elephant Capital will leverage their substantial network in India and internationally, to aid the further expansion of ClinTec operations in India. The partnership will also facilitate expansion into the Asia Pacific region with ClinTec’s long established Bangalore office serving as the regional hub for clinical research activity.
Commenting on the transaction, Gaurav Burman said. “We are looking forward to a long-term partnership with ClinTec International and building on all that has been achieved to date. As well as bringing to ClinTec, our expertise in finance and creating corporate global organizations, we look to preserve the fine values and unique culture of ClinTec which has made it such a well respected and successful global organization”.
With an investment of £8 Million GBP, Elephant has acquired a significant minority stake in ClinTec. Through this investment, Elephant has entered the attractive clinical research base, where ClinTec operates as a global provider of outsourcing solutions addressing the drug development lifecycle. Managing Partner of Elephant Capital LLP, Gaurav Burman, and Non-Executive Director of Elephant Capital Plc, Jim Hauslein, have also made personal co-investments in this transaction.
ClinTec has elected to strengthen the Board of the company as part of the transaction, and as such Gaurav Burman, Dr Anand Burman and Jim Hauslein will take up seats on the Board. Gaurav Burman founded Elephant Capital in 2007; the company counts some of the leading financial institutional investors in the UK and Europe amongst its shareholders and is actively supported by the Burman family itself.
Dr Anand Burman is the Chairman of FMCG company Dabur, and brings a wealth of experience in the healthcare sector and oncology. Jim Hauslein, who has previously served as Chairman and CEO of Sunglass Hut International, which was turned into a global enterprise during his tenure, provides invaluable business experience of growing corporates internationally.
Elephant focuses on differentiated businesses which are able to leverage the potential India holds as an emerging powerhouse within the global economy. ClinTec was identified as just such a company, as it has established a solid presence in India and is one of the first-movers in the Clinical Research Services arena to enter India in 2002.
Elephant Capital will leverage their substantial network in India and internationally, to aid the further expansion of ClinTec operations in India. The partnership will also facilitate expansion into the Asia Pacific region with ClinTec’s long established Bangalore office serving as the regional hub for clinical research activity.
Commenting on the transaction, Gaurav Burman said. “We are looking forward to a long-term partnership with ClinTec International and building on all that has been achieved to date. As well as bringing to ClinTec, our expertise in finance and creating corporate global organizations, we look to preserve the fine values and unique culture of ClinTec which has made it such a well respected and successful global organization”.
